Rapid Therapeutic Science Laboratories, Inc. (RTSL) Enterprise Value (2016 - 2023)
Rapid Therapeutic Science Laboratories' Enterprise Value history spans 8 years, with the latest figure at -$2160.0 for Q2 2023.
- For Q2 2023, Enterprise Value rose 98.07% year-over-year to -$2160.0; the TTM value through Jun 2023 reached -$2160.0, up 98.07%, while the annual FY2021 figure was -$192484.0, 61.44% up from the prior year.
- Enterprise Value for Q2 2023 was -$2160.0 at Rapid Therapeutic Science Laboratories, up from -$17572.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$1334.0 in Q1 2019 and bottomed at -$919707.0 in Q3 2021.
- The 5-year median for Enterprise Value is -$124189.5 (2019), against an average of -$172987.6.
- The largest annual shift saw Enterprise Value tumbled 10111.09% in 2020 before it skyrocketed 98.07% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$136215.0 in 2019, then tumbled by 266.44% to -$499146.0 in 2020, then soared by 61.44% to -$192484.0 in 2021, then skyrocketed by 41.73% to -$112164.0 in 2022, then surged by 98.07% to -$2160.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Enterprise Value are -$2160.0 (Q2 2023), -$17572.0 (Q1 2023), and -$112164.0 (Q2 2022).